3.171 - AMICOR (26)
#Com Dra. Valderês A. Robinson Achutti (*13/06/1931 +15/06/2021)
No século passado, nas Montanhas Rochosas, no Canadá.Tabagismo e Gravidez
#History Channel
|
|
#Med Page Today
Opening Blood-Brain Barrier to Deliver Alzheimer's Drug Shows Promise — Focused ultrasound helped aducanumab reduce amyloid-beta levels by Judy George, Deputy Managing Editor, MedPage Today January 3, 2024
Aducanumab (Aduhelm) infusions combined with focused ultrasound led to lower cerebral amyloid-beta levels in Alzheimer's disease, a proof-of-concept trial showed.
The investigational treatment involved creating an opening in the blood-brain barrier with MRI-guided focused ultrasound to boost drug delivery./.../
|
#IHME
|
#Quanta Magazine
|
COMPUTER SCIENCE
‘Magical’ Error Correction Scheme Proved Inherently Inefficient
Locally correctable codes need barely any information to fix errors, but they’re extremely long. Now we know that the simplest versions can’t get any shorter.
Read article
#
Top 10 Most Read Pieces from 2023
#MEDSCAPE
Proper care of teeth and gums may offer benefits beyond oral health, including improving brain health, new research suggests.
In a large observational study of middle-aged adults without stroke or dementia, poor oral health was strongly associated with multiple neuroimaging markers of white matter injury.
"Because the neuroimaging markers evaluated in this study precede and are established risk factors of stroke and dementia, our results suggest that oral health, an easily modifiable process, may be a promising target for very early interventions focused on improving brain health," wrote the authors, led by Cyprien Rivier, MD, MS, with the Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.
The study was published online on December 20, 2023, in Neurology.
#Nature aging
Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles
Nature Aging (2024)
Abstract
Alzheimer’s disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity is critical for AD drug development. Here we define AD molecular subtypes using mass spectrometry proteomics in cerebrospinal fluid, based on 1,058 proteins, with different levels in individuals with AD (n = 419) compared to controls (n = 187). These AD subtypes had alterations in protein levels that were associated with distinct molecular processes: subtype 1 was characterized by proteins related to neuronal hyperplasticity; subtype 2 by innate immune activation; subtype 3 by RNA dysregulation; subtype 4 by choroid plexus dysfunction; and subtype 5 by blood–brain barrier impairment. Each subtype was related to specific AD genetic risk variants, for example, subtype 1 was enriched with TREM2 R47H. Subtypes also differed in clinical outcomes, survival times and anatomical patterns of brain atrophy. These results indicate molecular heterogeneity in AD and highlight the need for personalized medicine.
#World Congress of Cardiology
|
# Popular Mechanics
|
No comments:
Post a Comment